Pharmaceuticals North America (NAFTA) Industry Guide 2019-2028


Summary

The NAFTA Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.


Key Highlights

  • The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The pharmaceuticals industry within the NAFTA countries had a total market value of $546.6 billion in 2023.The Mexico was the fastest growing country, with a CAGR of 7% over the 2019-23 period.
  • Within the pharmaceuticals industry, the US is the leading country among the NAFTA bloc, with market revenues of $496.7 billion in 2023. This was followed by Canada and Mexico, with a value of $32.3 and $17.7 billion, respectively.
  • The US is expected to lead the pharmaceuticals industry in the NAFTA bloc, with a value of $579.7 billion in 2028, followed by Canada and Mexico with expected values of $37.7 and $22.5 billion, respectively.




Scope

  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA pharmaceuticals market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA pharmaceuticals market
  • Leading company profiles reveal details of key pharmaceuticals market players’ NAFTA operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA pharmaceuticals market with five year forecasts
  • Compares data from the US, Canada and Mexico, alongside individual chapters on each country




Reasons To Buy

  • What was the size of the NAFTA pharmaceuticals market by value in 2023?
  • What will be the size of the NAFTA pharmaceuticals market in 2028?
  • What factors are affecting the strength of competition in the NAFTA pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitors in the NAFTA pharmaceuticals market?